Medicamen Biotech Live Share Price Today, Share Analysis and Chart

Name: Medicamen Biotech Ltd.: Is Infosys Ltd. worth buying?
Item: Medicamen Biotech Ltd.
Rating: 2.269208375
Author: Trendlyne DVM scores

Mid-range Performer

Iran war impact

Based on the company's disclosures in its Annual Report 2024-25 and the latest Quarterly Results for FY26, the impact of the Middle East conflict on Medicamen Biotech Ltd. is analyzed below: ##### Impact Outline: Minimal to Low Medicamen ...

244.60 3.41 (1.41%)

51.27% Fall from 52W High

24,635

NSE+BSE Volume

NSE 13 Apr, 2026 2:01 PM (IST)

Loading... You have run out of DVM views!

Subscribe now to see details

Medium Financial Strength

- / 100

Mid Valuation

- / 100

Technically Neutral

35.4 / 100

Mid-range Performer These stocks have average quality, financial and technical momentum, indicating a mid range performer View Similar Embed DVM

No estimates available

Medicamen Biotech Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Is Medicamen Biotech Ltd. worth buying?

39 Votes:

Buy 76.92%

Sell 17.95%

Hold 5.13%

Medicamen Biotech Live Share Price Today, Share Analysis and Chart

Based on the company's disclosures in its Annual Report 2024-25 and the latest Quarterly Results for FY26, the impact of the Middle East conflict on Medicamen Biotech Ltd. is analyzed below: ##### Impact Outline: Minimal to Low Medicamen ...

51.27% Fall from 52W High

SWOT Analysis

Medicamen Biotech Live Price Chart